Lixte Biotechnology Holdings Inc
Company Profile
Business description
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Contact
680 East Colorado Boulevard
Suite 180
PasadenaCA91101
USAT: +1 631 830-7092
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
4
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,635.80 | 4.30 | 0.05% |
| CAC 40 | 7,826.79 | 1.34 | -0.02% |
| DAX 40 | 24,226.49 | 198.84 | 0.83% |
| Dow JONES (US) | 42,343.65 | 740.58 | 1.78% |
| FTSE 100 | 8,778.05 | 60.08 | 0.69% |
| HKSE | 23,230.43 | 151.56 | -0.65% |
| NASDAQ | 19,199.16 | 461.96 | 2.47% |
| Nikkei 225 | 37,860.50 | 136.39 | 0.36% |
| NZX 50 Index | 12,366.32 | 216.01 | -1.72% |
| S&P 500 | 5,921.54 | 118.72 | 2.05% |
| S&P/ASX 200 | 8,405.40 | 2.20 | -0.03% |
| SSE Composite Index | 3,342.93 | 2.24 | 0.07% |